noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

Eisai Inc.

Results Eisai Inc.

Eisai Inc.

EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025

-3d
Eisai Inc.

“LEQEMBI®” (Lecanemab) Approved for Slowing the Progression of Early Alzheimer’s Disease in Singapore

6/3
Eisai Inc.

MedTech Breakthrough Recognizes Eisai, Biogen, and Medisafe for Alzheimer’s Disease Treatment Innovation

5/29
Eisai Inc.

Eisai Obtains Favorable Decision in Patent Infringement Litigation Related to Lenvatinib in the U.S.

5/28
Eisai Inc.

MedTech Breakthrough Awards Recognizes Eisai, Biogen, and MediSafe for Alzheimer’s Disease Treatment Innovation

5/28
Eisai Inc.

New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO® (Lemborexant) in China

5/28
Eisai Inc.

Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025

5/20
Eisai Inc.

Leqembi® (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

4/16
Eisai Inc.

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission

4/14
Eisai Inc.

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission

4/2